サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1625473

去勢抵抗性前立腺がん市場、規模、シェア、動向、産業分析レポート：治療法別、地域別 - 市場予測、2025年～2034年

Castrate-Resistant Prostate Cancer Market Size, Share, Trends, Industry Analysis Report: By Therapy and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 128 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
去勢抵抗性前立腺がん市場、規模、シェア、動向、産業分析レポート：治療法別、地域別 - 市場予測、2025年～2034年
出版日: 2024年12月01日
発行: Polaris Market Research
ページ情報: 英文 128 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、去勢抵抗性前立腺がん（CRPC）市場規模は2034年までに297億9,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

去勢抵抗性前立腺がん市場の成長は、特に高齢化社会における罹患率の増加に起因しています。前立腺がんは、より進行した治療抵抗性の段階に進行することが多いです。そのため、効果的な治療法に対する需要が高まり、標的治療や精密腫瘍学の進歩につながっています。Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; and Astellas Pharma, Incなどの主要企業は、先進的な製品と継続的なイノベーションでこの市場を牽引しています。CRPCの市場規模は、主要企業がアンドロゲン受容体阻害剤、免疫療法、その他の標的アプローチなどの新規治療に注力するにつれて拡大しています。こうした進歩は、包括的なCRPC治療オプションを提供する各社の市場シェア拡大に寄与しています。

去勢抵抗性前立腺がんの市場動向は、個別化医療や、より少ない副作用で有効性を高める併用療法へのシフトを示しています。北米は、強固なヘルスケアインフラ、高い認知度、確立された医療研究機関により、世界市場を独占しています。しかし、前立腺がんの罹患率の上昇、ヘルスケアへのアクセスの改善、新規治療に対する規制当局の支援により、アジア太平洋地域が最も高いCAGRを示すと予想されます。これらの地域における去勢抵抗性前立腺がん（CRPC）市場の成長は、腫瘍学の研究と治療に対する投資の増加という世界の広範な動向を反映しています。加えて、企業が製品パイプラインと地理的リーチを拡大しようとするため、提携やM&Aも盛んであり、去勢抵抗性前立腺がん市場の拡大にさらに拍車をかけています。

去勢抵抗性前立腺がん市場レポートハイライト

2024年の去勢抵抗性前立腺がん市場では、アンドロゲン濃度を低下させることで疾患の進行を遅らせるホルモン療法の有効性が実証されたことから、ホルモン療法分野が最大のシェアを占めています。

免疫療法分野は、身体の免疫系を利用して前立腺がん細胞を特異的に標的にして攻撃する能力があり、有望で侵襲性の低い治療選択肢を提供することから、予測期間中に最も高いCAGRを示すと予想されています。

2024年には、北米が、その先進ヘルスケアインフラと前立腺がんの高い有病率により、去勢抵抗性前立腺がん市場シェアを独占しました。

アジア太平洋市場は、先進的な治療オプションに対する意識の高まりと、がん治療における政府の支援策により、予測期間中に大きな成長が見込まれています。

世界の主な市場参入企業は、Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; and Dendreon Corporation.などです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の去勢抵抗性前立腺がん市場の洞察

  • 市場スナップショット
  • 去勢抵抗性前立腺がん市場力学
    • 促進要因と機会
      • 前立腺がんの発症率上昇
      • 高齢化人口の増加
    • 抑制要因と課題
      • 末期疾患に対する治療選択肢は限られている
  • PESTEL分析
  • 去勢抵抗性前立腺がんの市場動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の去勢抵抗性前立腺がん市場：治療法別

  • 主な調査結果
  • イントロダクション
  • 化学療法
  • ホルモン療法
  • 免疫療法
  • 放射線治療

第6章 世界の去勢抵抗性前立腺がん市場：地域別

  • 主な調査結果
  • イントロダクション
    • 去勢抵抗性前立腺がん市場評価：地域、2020-2034年
  • 北米
    • 北米：治療法別、2020-2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療法別、2020-2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：治療法別、2020-2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療法別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療法別、2020-2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第7章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第8章 企業プロファイル

  • Sanofi S.A.
  • Johnson & Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Corporation
図表

List of Tables:

Table 1 Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 2 North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 3 U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 4 Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 5 Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 6 UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 7 France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 8 Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 9 Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 10 Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 11 Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 12 Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 13 Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 14 Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 15 China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 16 India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 17 Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 18 Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 19 Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 20 South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 21 Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 22 Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 23 Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 24 Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 25 UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 26 Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 27 South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 28 Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 29 Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 30 Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 31 Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 32 Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

Table 33 Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

List of Figures:

Figure 1. Global Castrate-resistant Prostate Cancer Market, 2020-2034 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Therapy

Figure 7. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2024 & 2034 (USD Billion)

目次
Product Code: PM5332

The castrate-resistant prostate cancer (CRPC) market size is expected to reach USD 29.79 billion by 2034, according to a new study by Polaris Market Research. The report "Castrate-Resistant Prostate Cancer Market Share, Size, Trends, Industry Analysis Report: By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The castrate-resistant prostate cancer market growth is attributed to increasing incidence rates, especially among aging populations. Prostate cancer often progresses to a more advanced, treatment-resistant stage. Thus, the demand for effective therapies has grown, leading to advancements in targeted treatments and precision oncology. Key players such as Sanofi S.A.; Johnson & Johnson; Pfizer, Inc.; Bayer AG; and Astellas Pharma, Inc. drive this market with leading products and continued innovation. The CRPC market size has expanded as major companies focus on novel therapies such as androgen receptor inhibitors, immunotherapies, and other targeted approaches. Such advancements have contributed to increased market share among companies offering comprehensive CRPC treatment options.

The castrate-resistant prostate cancer market trends indicate a shift toward personalized medicine and combination therapies that offer enhanced efficacy with fewer side effects. North America dominates the global market due to robust healthcare infrastructure, high awareness, and established medical research institutions. However, Asia Pacific is expected to witness the highest CAGR due to rising prostate cancer incidence, improved healthcare access, and regulatory support for new treatments. The castrate-resistant prostate cancer market (CRPC) market growth in these regions reflects a broader global trend of increasing investments in oncology research and treatment. Additionally, partnerships, and mergers and acquisitions are prevalent, as companies seek to expand their product pipelines and geographic reach, further fueling the castrate-resistant prostate cancer market expansion.

Castrate-Resistant Prostate Cancer Market Report Highlights

In terms of therapy, in 2024, the hormonal therapy segment accounted for the largest share of the castrate-resistant prostate cancer market due to its proven effectiveness in slowing disease progression by reducing androgen levels.

The immunotherapy segment is expected to witness the highest CAGR during the forecast period due to its ability to harness the body's immune system to specifically target and attack prostate cancer cells, offering a promising and less invasive treatment option.

In 2024, North America dominated the castrate-resistant prostate cancer market share due to its advanced healthcare infrastructure and high prevalence of prostate cancer.

The Asia Pacific market is expected to witness significant growth during the forecast period due to the growing awareness of advanced treatment options and supportive government initiatives in cancer care.

A few global key market players are Sanofi S.A.; Johnson and Johnson; Pfizer, Inc.; Bayer AG; Abbott Laboratories; GlaxoSmithKline PLC; Northwest Biotherapeutics, Inc.; Active Biotech AB; Astellas Pharma, Inc; and Dendreon Corporation.

Polaris Market Research has segmented the castrate-resistant prostate cancer market report on the basis of therapy, and region:

By Therapy Outlook (Revenue, USD Billion; 2020-2034)

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiotherapy

By Regional Outlook (Revenue, USD Billion; 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Castrate-resistant Prostate Cancer Market Insights

  • 4.1. Castrate-resistant Prostate Cancer Market - Market Snapshot
  • 4.2. Castrate-resistant Prostate Cancer Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Incidence of Prostate Cancer
      • 4.2.1.2. Growing Geriatric Population
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Treatment Options for Late-stage Disease
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Castrate-resistant Prostate Cancer Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Castrate-resistant Prostate Cancer Market, by Therapy

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 5.3. Chemotherapy
    • 5.3.1. Global Castrate-resistant Prostate Cancer Market, by Chemotherapy, by Region, 2020-2034 (USD Billion)
  • 5.4. Hormonal Therapy
    • 5.4.1. Global Castrate-resistant Prostate Cancer Market, by Hormonal Therapy, by Region, 2020-2034 (USD Billion)
  • 5.5. Immunotherapy
    • 5.5.1. Global Castrate-resistant Prostate Cancer Market, by Immunotherapy, by Region, 2020-2034 (USD Billion)
  • 5.6. Radiotherapy
    • 5.6.1. Global Castrate-resistant Prostate Cancer Market, by Radiotherapy, by Region, 2020-2034 (USD Billion)

6. Global Castrate-resistant Prostate Cancer Market, by Geography

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Castrate-resistant Prostate Cancer Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 6.3. Castrate-resistant Prostate Cancer Market - North America
    • 6.3.1. North America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.3.2. Castrate-resistant Prostate Cancer Market - U.S.
      • 6.3.2.1. U.S.: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.3.3. Castrate-resistant Prostate Cancer Market - Canada
      • 6.3.3.1. Canada: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.4. Castrate-resistant Prostate Cancer Market - Europe
    • 6.4.1. Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.2. Castrate-resistant Prostate Cancer Market - UK
      • 6.4.2.1. UK: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.3. Castrate-resistant Prostate Cancer Market - France
      • 6.4.3.1. France: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.4. Castrate-resistant Prostate Cancer Market - Germany
      • 6.4.4.1. Germany: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.5. Castrate-resistant Prostate Cancer Market - Italy
      • 6.4.5.1. Italy: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.6. Castrate-resistant Prostate Cancer Market - Spain
      • 6.4.6.1. Spain: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.7. Castrate-resistant Prostate Cancer Market - Netherlands
      • 6.4.7.1. Netherlands: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.8. Castrate-resistant Prostate Cancer Market - Russia
      • 6.4.8.1. Russia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.4.9. Castrate-resistant Prostate Cancer Market - Rest of Europe
      • 6.4.9.1. Rest of Europe: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.5. Castrate-resistant Prostate Cancer Market - Asia Pacific
    • 6.5.1. Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.2. Castrate-resistant Prostate Cancer Market - China
      • 6.5.2.1. China: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.3. Castrate-resistant Prostate Cancer Market - India
      • 6.5.3.1. India: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.4. Castrate-resistant Prostate Cancer Market - Malaysia
      • 6.5.4.1. Malaysia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.5. Castrate-resistant Prostate Cancer Market - Japan
      • 6.5.5.1. Japan: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.6. Castrate-resistant Prostate Cancer Market - Indonesia
      • 6.5.6.1. Indonesia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.7. Castrate-resistant Prostate Cancer Market - South Korea
      • 6.5.7.1. South Korea: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.8. Castrate-resistant Prostate Cancer Market - Australia
      • 6.5.8.1. Australia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.5.9. Castrate-resistant Prostate Cancer Market - Rest of Asia Pacific
      • 6.5.9.1. Rest of Asia Pacific: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.6. Castrate-resistant Prostate Cancer Market - Middle East & Africa
    • 6.6.1. Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.2. Castrate-resistant Prostate Cancer Market - Saudi Arabia
      • 6.6.2.1. Saudi Arabia: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.3. Castrate-resistant Prostate Cancer Market - UAE
      • 6.6.3.1. UAE: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.4. Castrate-resistant Prostate Cancer Market - Israel
      • 6.6.4.1. Israel: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.5. Castrate-resistant Prostate Cancer Market - South Africa
      • 6.6.5.1. South Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.6.6. Castrate-resistant Prostate Cancer Market - Rest of Middle East & Africa
      • 6.6.6.1. Rest of Middle East & Africa: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
  • 6.7. Castrate-resistant Prostate Cancer Market - Latin America
    • 6.7.1. Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.2. Castrate-resistant Prostate Cancer Market - Mexico
      • 6.7.2.1. Mexico: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.3. Castrate-resistant Prostate Cancer Market - Brazil
      • 6.7.3.1. Brazil: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.4. Castrate-resistant Prostate Cancer Market - Argentina
      • 6.7.4.1. Argentina: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)
    • 6.7.5. Castrate-resistant Prostate Cancer Market - Rest of Latin America
      • 6.7.5.1. Rest of Latin America: Castrate-resistant Prostate Cancer Market, by Therapy, 2020-2034 (USD Billion)

7. Competitive Landscape

  • 7.1. Expansion and Acquisition Analysis
    • 7.1.1. Expansion
    • 7.1.2. Acquisitions
  • 7.2. Partnerships/Collaborations/Agreements/Exhibitions

8. Company Profiles

  • 8.1. Sanofi S.A.
    • 8.1.1. Company Overview
    • 8.1.2. Financial Performance
    • 8.1.3. Product Benchmarking
    • 8.1.4. Recent Development
  • 8.2. Johnson & Johnson
    • 8.2.1. Company Overview
    • 8.2.2. Financial Performance
    • 8.2.3. Product Benchmarking
    • 8.2.4. Recent Development
  • 8.3. Pfizer, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Financial Performance
    • 8.3.3. Product Benchmarking
    • 8.3.4. Recent Development
  • 8.4. Bayer AG
    • 8.4.1. Company Overview
    • 8.4.2. Financial Performance
    • 8.4.3. Product Benchmarking
    • 8.4.4. Recent Development
  • 8.5. Abbott Laboratories
    • 8.5.1. Company Overview
    • 8.5.2. Financial Performance
    • 8.5.3. Product Benchmarking
    • 8.5.4. Recent Development
  • 8.6. GlaxoSmithKline PLC
    • 8.6.1. Company Overview
    • 8.6.2. Financial Performance
    • 8.6.3. Product Benchmarking
    • 8.6.4. Recent Development
  • 8.7. Northwest Biotherapeutics, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Financial Performance
    • 8.7.3. Product Benchmarking
    • 8.7.4. Recent Development
  • 8.8. Active Biotech AB
    • 8.8.1. Company Overview
    • 8.8.2. Financial Performance
    • 8.8.3. Product Benchmarking
    • 8.8.4. Recent Development
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Financial Performance
    • 8.9.3. Product Benchmarking
    • 8.9.4. Recent Development
  • 8.10. Dendreon Corporation
    • 8.10.1. Company Overview
    • 8.10.2. Financial Performance
    • 8.10.3. Product Benchmarking
    • 8.10.4. Recent Development